Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes.

Scientific reports - 11 Feb 2024

Akinjiyan Favour A, Nassief George, Phillipps Jordan, Adeyelu Tolulope, Elliott Andrew, Abdulla Farah, Zhou Alice Y, Souroullas George, Kim Kevin B, Vanderwalde Ari, Park Soo J, Ansstas George

Abstract excerpt

ARID genes encode subunits of SWI/SNF chromatin remodeling complexes and are frequently mutated in human cancers. We investigated the correlation between ARID mutations, molecular features, and clinical outcomes in melanoma patients. Cutaneous melanoma samples (n = 1577) were analyzed by next-generation sequencing. Samples were stratified by pathogenic/likely pathogenic mutation in ARID genes (ARID1A/2/1B/5B)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kaplan-Meier Estimate

Share to Melanoma

Share to Melanoma and MAPK Pathways

Share to Mutation

Share to Skin Neoplasms

Share to Transcription Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 38341515
DOI: 10.1038/s41598-024-54136-3
PMCID: PMC10858967

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes.PMID 38341515Read ↗

ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma.Semantic proximity Read ↗

Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study.Semantic proximity Read ↗

Integrated molecular drivers coordinate biological and clinical states in melanoma.Semantic proximity Read ↗

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapySemantic proximity Read ↗

PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer.Semantic proximity Read ↗

Illuminating HLA-DPA1 and HSH2D as Potential Prognostic Biomarkers by Weighted Gene Co-Expression Network Analysis for NRAS-Mutant Skin Cutaneous MelanomaSemantic proximity Read ↗

Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy.Semantic proximity Read ↗

ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic TargetSemantic proximity Read ↗

Mutational profile of atypical fibroxanthoma and pleomorphic dermal sarcoma further expands the spectrum of genomic alterations in rare cutaneous neoplasms.Semantic proximity Read ↗

Targeting ARID1A mutations in cancer.Semantic proximity Read ↗

ARID1A and Its Impact Across the Hallmarks of CancerSemantic proximity Read ↗

Mining database for the clinical significance and prognostic value of ESRP1 in skin cutaneous melanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.